Hims & Hers Health Inc. Aktie News

Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market. However, the rally is fading rather quickly.

GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.

The S&P 500 and Nasdaq composite flip lower Thursday on banking worries. Broadcom, Hims & Hers Health, and Oracle are top names to watch.

I am upgrading Hims & Hers Health, Inc. to a Buy with an $80 price target, implying 30% upside. The new 'Hers' specialty in Menopause is expected to help the company drive over $1B in Hers segment revenue by 2026, diversifying away from GLP-1 volatility. Despite a recent sequential revenue decline and negative cash flow, Hims & Hers maintains strong subscriber growth and ambitious 2030 targets ...

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is creating revenue sources beyond its debated compounded GLP-1 obesity treatments. With shares already up 150% year-to-date and trading at approximately $60, the critical question now is: could HIMS ...

Shares of Hims & Hers (HIMS 16.20%) jumped 9% in trading on Wednesday after the company announced an expansion into menopause and perimenopause specialties on the Hers app. This is the kind of product expansion that will drive greater adoption and higher growth long term, as Travis Hoium highlights in this video.

Healthcare products specialist Hims & Hers Health (HIMS 16.20%) stock passed the most crucial exam of all on Wednesday, as investors gave it the thumbs-up. The shares ended the day more than 16% higher in price, thanks to the company's reveal that it's pushing into a potentially lucrative new segment.

Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.